Volume 91 Issue 36 | p. 16 | News of The Week
Issue Date: September 9, 2013 | Web Date: September 5, 2013

Firms Spar Over Hepatitis Drug

Patents: Merck & Co., too, claims a stake in hepatitis C drug from Gilead
Department: Business
Keywords: HCV, antivirals, pharmaceuticals, biotech

As Gilead prepares for the launch of sofosbuvir, a small-molecule hepatitis C treatment that is expected to rake in billions of dollars annually, competitors are angling for a piece of the action. The latest firm to come forward is Merck & Co., which alleges that sofosbuvir’s structure is covered by patents generated in its search for hepatitis C treatments.

According to the Centers for Disease Control & Prevention, roughly 3.2 million Americans are . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society